280 related articles for article (PubMed ID: 25297949)
1. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.
Zientek MA; Youdim K
Drug Metab Dispos; 2015 Jan; 43(1):163-81. PubMed ID: 25297949
[TBL] [Abstract][Full Text] [Related]
2. The role of drug metabolizing enzymes in clearance.
Di L
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):379-93. PubMed ID: 24392841
[TBL] [Abstract][Full Text] [Related]
3. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
4. Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.
Argikar UA; Potter PM; Hutzler JM; Marathe PH
AAPS J; 2016 Nov; 18(6):1391-1405. PubMed ID: 27495117
[TBL] [Abstract][Full Text] [Related]
5. Reaction phenotyping to assess victim drug-drug interaction risks.
Di L
Expert Opin Drug Discov; 2017 Nov; 12(11):1105-1115. PubMed ID: 28820269
[TBL] [Abstract][Full Text] [Related]
6. Reaction phenotyping in drug discovery: moving forward with confidence?
Williams JA; Hurst SI; Bauman J; Jones BC; Hyland R; Gibbs JP; Obach RS; Ball SE
Curr Drug Metab; 2003 Dec; 4(6):527-34. PubMed ID: 14683480
[TBL] [Abstract][Full Text] [Related]
7. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase.
Hutzler JM; Obach RS; Dalvie D; Zientek MA
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):153-68. PubMed ID: 23231678
[TBL] [Abstract][Full Text] [Related]
8. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
9. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Drug Metabolism Using Liver Microsomes.
Knights KM; Stresser DM; Miners JO; Crespi CL
Curr Protoc Pharmacol; 2016 Sep; 74():7.8.1-7.8.24. PubMed ID: 27636111
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
[TBL] [Abstract][Full Text] [Related]
12. Designing better drugs: predicting cytochrome P450 metabolism.
de Groot MJ
Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
[TBL] [Abstract][Full Text] [Related]
13. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
[TBL] [Abstract][Full Text] [Related]
14. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
Strelevitz TJ; Orozco CC; Obach RS
Drug Metab Dispos; 2012 Jul; 40(7):1441-8. PubMed ID: 22522748
[TBL] [Abstract][Full Text] [Related]
15. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
[TBL] [Abstract][Full Text] [Related]
18. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.
McGinnity DF; Parker AJ; Soars M; Riley RJ
Drug Metab Dispos; 2000 Nov; 28(11):1327-34. PubMed ID: 11038161
[TBL] [Abstract][Full Text] [Related]
19. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
20. 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes.
Liu R; Liu J; Tawa G; Wallqvist A
J Chem Inf Model; 2012 Jun; 52(6):1698-712. PubMed ID: 22631565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
